ID: h-dfb6bf5d59
Hypothesis
TGF-β1-SMAD Signaling Dysregulation
Healthy astrocytes secrete TGF-β1, which activates SMAD signaling and upregulates microtubule-associated proteins and motor proteins, restoring RBP transport.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 7 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
Healthy astrocytes secrete TGF-β1, which activates SMAD signaling and upregulates microtubule-associated proteins and motor proteins, restoring RBP transport. This hypothesis is deprioritized because astrocyte-derived TGF-β1 in ALS literature is typically described as upregulated and pathogenic/immunosuppressive, not missing and protective.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Epigenetic Silencing<br/>REST Convergence Hub Overactivation"]
B["Neuronal Gene Repression<br/>REST Binding to RE1 Elements"]
C["HDAC Recruitment<br/>Histone Deacetylase Co-Repressor Complex"]
D["DNMT Activity<br/>CpG Methylation of Neuronal Promoters"]
E["Neuronal Function Loss<br/>Synaptic Plasticity and Survival Gene Silencing"]
F["Combinatorial HDAC/DNMT Inhibition<br/>Vorinostat plus Azacytidine"]
A --> B
B --> C
B --> D
C --> E
D --> E
F -.->|"relieves"| C
F -.->|"relieves"| D
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix7 supports3 contradicts
Supports
TGF-β1 prevents TDP-43 mislocalization in cultured neurons under some conditions
Supports
SMAD3 promotes autophagy dysregulation by triggering lysosome depletion in tubular epithelial cells in diabetic nephropathy.
Supports
Aberrant TGF-β1 signaling activation by MAF underlies pathological lens growth in high myopia.
Supports
Investigating dysregulation of TGF-β1/SMAD3 signaling in atopic dermatitis: a molecular and immunohistochemical analysis.
Supports
Tanshinone IIA attenuates silica-induced pulmonary fibrosis via inhibition of TGF-β1-Smad signaling pathway.
Contradicts
Astrocyte-derived TGF-β1 is often upregulated in ALS and accelerates ALS progression in mice
Contradicts
TGF-β1 is reduced in ALS CSF and tissue only in certain contexts; literature generally supports pathogenic rather than protective role
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — TGFB1;
No curated PDB or AlphaFold mapping for TGFB1; yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TGFB1; TGFBR2; SMAD2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 1.0%
Volatility
Medium
0.0222
Events (7d)
3
Price History
▲19.1%💾 Resource Usage
LLM Tokens
10,463
$0.0314
Total Cost
$0.0314
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF primary rodent cortical neurons or human iPSC-derived neurons are treated with exogenous TGF-β1 (5-10 ng/mL) for 24-48 hours to activate SMAD2/3 signaling, THEN protein expression of microtubule-as | Increased expression of MAP1B, MAP2, KIF1A, KIF5 proteins by ≥30% following TGF-β1 treatment, with confirmed SMAD2/3 phosphorylation | — no observation — | pending | 0.45 |
| IF astrocyte-conditioned medium from age-matched control subjects versus ALS patients is applied to healthy neurons, THEN neurons exposed to control astrocyte medium will show significantly faster RBP | Control astrocyte-conditioned medium produces faster RBP transport velocity (μm/s) than ALS astrocyte-conditioned medium, despite elevated TGF-β1 secretion in A | — no observation — | pending | 0.40 |
🔮 Falsifiable Predictions (2)
pendingconf 45%
IF primary rodent cortical neurons or human iPSC-derived neurons are treated with exogenous TGF-β1 (5-10 ng/mL) for 24-48 hours to activate SMAD2/3 signaling, THEN protein expression of microtubule-associated proteins (MAP1B, MAP2) and motor proteins (KIF1A, KIF5) will increase by ≥30% relative to v
Predicted outcome: Increased expression of MAP1B, MAP2, KIF1A, KIF5 proteins by ≥30% following TGF-β1 treatment, with confirmed SMAD2/3 phosphorylation
Falsification: No significant increase (p>0.05) or decrease in microtubule-associated protein and motor protein expression following TGF-β1 treatment, indicating the pathway does not upregulate these proteins as hyp
pendingconf 40%
IF astrocyte-conditioned medium from age-matched control subjects versus ALS patients is applied to healthy neurons, THEN neurons exposed to control astrocyte medium will show significantly faster RBP transport (measured as mean velocity of TDP-43 or FUS granules) compared to neurons exposed to ALS
Predicted outcome: Control astrocyte-conditioned medium produces faster RBP transport velocity (μm/s) than ALS astrocyte-conditioned medium, despite elevated TGF-β1 secr
Falsification: Neurons exposed to ALS astrocyte-conditioned medium show equal or improved RBP transport compared to control medium, indicating TGF-β1 elevation is not suppressing transport; or ALS astrocytes do not
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.